Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PH 762

Next Previous
Drug Profile

PH 762

Alternative Names: PH 762 adoptive cell therapy; PH-762; PH762-ACT; RXI 762-ACT

Latest Information Update: 29 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Phio Pharmaceuticals
  • Developer AgonOx; Phio Pharmaceuticals
  • Class Antineoplastics; Gene therapies; Immunotherapies; Small interfering RNA; T lymphocyte cell therapies
  • Mechanism of Action Programmed cell death 1 receptor expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Malignant melanoma; Merkel cell carcinoma; Solid tumours; Squamous cell cancer

Most Recent Events

  • 31 Dec 2024 Phio Pharmaceuticals has patent protection for INTASYL™technology
  • 31 May 2024 Phio Pharmaceuticals terminates Clinical Co-Development Agreement with AgonOx for clinical development of PH 762
  • 05 Apr 2024 Interim efficacy and adverse events data from a phase I trial in solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top